Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AN2 Therapeutics Inc (ANTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: ANTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.5
1 Year Target Price $1.5
| 0 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 69.05% | Avg. Invested days 47 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 34.70M USD | Price to earnings Ratio - | 1Y Target Price 1.5 |
Price to earnings Ratio - | 1Y Target Price 1.5 | ||
Volume (30-day avg) 3 | Beta -0.07 | 52 Weeks Range 0.97 - 1.68 | Updated Date 09/12/2025 |
52 Weeks Range 0.97 - 1.68 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.54% | Return on Equity (TTM) -44.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -28211771 | Price to Sales(TTM) - |
Enterprise Value -28211771 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.11 | Shares Outstanding 27326200 | Shares Floating 17736594 |
Shares Outstanding 27326200 | Shares Floating 17736594 | ||
Percent Insiders 25.39 | Percent Institutions 39.54 |
Upturn AI SWOT
AN2 Therapeutics Inc
Company Overview
History and Background
AN2 Therapeutics Inc. is a biopharmaceutical company focused on developing novel therapies for rare, chronic, and serious infectious diseases with high unmet needs. Founded in 2021, it is a relatively new player in the pharmaceutical industry.
Core Business Areas
- Infectious Disease Therapeutics Development: Focuses on the discovery, development, and commercialization of therapies for infectious diseases. Their lead product candidate is currently being developed for treatment-refractory nontuberculous mycobacterial (NTM) lung disease.
Leadership and Structure
The leadership team consists of experienced executives in the biopharmaceutical industry. Their structure is typical for a clinical-stage company, with departments focused on research and development, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- Epetraborole: AN2 Therapeutics' lead product candidate, Epetraborole, is being developed for treatment-refractory NTM lung disease. Market share data is not yet available as the product is still in clinical development. Competitors include existing antibiotic therapies, but Epetraborole aims to address treatment-refractory cases. Competitors: Insmed (INSM), multiple generic antibiotics.
Market Dynamics
Industry Overview
The pharmaceutical industry focusing on infectious diseases is characterized by significant unmet needs, particularly for rare and treatment-refractory conditions. The market is competitive, with large pharmaceutical companies and smaller biotechs vying for market share.
Positioning
AN2 Therapeutics is positioned as a company focused on addressing unmet medical needs in niche infectious disease markets. Their competitive advantage lies in their novel therapeutic approach and focus on treatment-refractory NTM lung disease.
Total Addressable Market (TAM)
The total addressable market for NTM lung disease is estimated to be significant, potentially reaching billions of dollars annually, given the prevalence and high cost of treatment, particularly in treatment-refractory cases. AN2's position is to capture a significant portion of this market with Epetraborole, assuming successful clinical trials and regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Focus on unmet medical needs
- Experienced management team
- Lead product candidate addressing a significant market opportunity
Weaknesses
- Early-stage company with limited revenue
- Dependence on the success of Epetraborole
- High R&D expenses
- Limited commercial infrastructure
Opportunities
- Successful clinical trials and regulatory approval of Epetraborole
- Expansion into other infectious disease indications
- Partnerships with larger pharmaceutical companies
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing therapies and new entrants
- Changes in the healthcare landscape
Competitors and Market Share
Key Competitors
- INSM
- TBIO
Competitive Landscape
AN2 Therapeutics is competing in the NTM lung disease market. Insmed currently dominates this market. AN2's primary competition is with current treatment regimes, and their success hinges on demonstrating superiority, particularly in refractory cases.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by the progression of Epetraborole through clinical trials.
Future Projections: Future growth is dependent on the successful development and commercialization of Epetraborole. Analyst estimates vary widely based on the perceived probability of success.
Recent Initiatives: Recent initiatives include advancing Epetraborole through clinical trials and exploring potential partnerships.
Summary
AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare infectious diseases. Its success hinges on the progress of its lead candidate, Epetraborole. A key risk is the inherent uncertainty of clinical trials. AN2 needs to focus on successful trial outcomes and strategic partnerships to maximize its potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is based on estimates and may not be precise. Future projections are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AN2 Therapeutics Inc
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2022-03-25 | Co-Founder, CEO, President & Chairman of the Board Mr. Eric E. Easom | ||
Sector Healthcare | Industry Biotechnology | Full time employees 22 | Website https://www.an2therapeutics.com |
Full time employees 22 | Website https://www.an2therapeutics.com | ||
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.